Senores Pharmaceuticals Q1 FY27: estimates and targets

Stock snapshot ahead of results season

Senores Pharmaceuticals Ltd. (NSE: SENORES, BSE: 544319) is being watched as investors position for the July to August 2026 results season for the quarter ended June 2026. The stock was cited trading around Rs. 1,382, with another reference point showing Rs. 1,381.90 on the NSE at 4:00 PM on 03 July. A separate data point also listed the stock at Rs. 1,319.10 as of 29 June 2026, highlighting the usual variation across timestamps and sources. The company is classified under Pharmaceuticals and Drugs and operates in the pharmaceuticals and life sciences space. In the preview note, the market capitalisation is cited at Rs. 6,356 crore. The same note also mentions a price-to-earnings multiple of 52.3 at the time of writing.

What is driving attention on Q1 FY27 numbers

The immediate trigger is the expectation-setting around Senores Pharmaceuticals Q1 FY27, with a published estimate range for revenue and profit after tax (PAT). The estimate framework described is a trailing-growth approach anchored to a Q1 FY26 base of Rs. 141 crore revenue and Rs. 21 crore net profit. The most recent year-on-year growth signal referenced is from Q4 FY26, which is used to build the Q1 FY27 preview range. Investors typically focus on whether recent operating momentum sustains into the next quarter, especially when valuation multiples are elevated. The preview also provides a 12-month target band, which becomes a reference for near-term positioning. While these are estimates, the key point is that the market is using a defined base period and a recent growth signal to frame expectations.

Q1 FY27 estimates: revenue, PAT and timeline

The Q1 FY27 estimates cited in the note place revenue at Rs. 197 to 227 crore and PAT at Rs. 28 to 36 crore. The same table pegs year-on-year growth at +50.0% for both revenue and PAT versus Q1 FY26 actuals. The results date is described as July to August 2026 (indicative), aligning with the broader results season calendar. Alongside operating expectations, a 12-month target range of Rs. 1,658 to 1,838 is stated as a Uniresearch estimate. The note characterises the stance as a “constructive bias,” while still anchoring the story on the published ranges. These metrics form the core checklist investors will compare against when the company reports.

Recent reported quarter: the Q4 FY26 base used in the preview

Ahead of Q1 FY27, the most recent reported quarter cited in the preview is Q4 FY26, with revenue of Rs. 193 crore and net profit of Rs. 37 crore. Separately, another set of disclosed metrics lists Q4 FY26 revenue from operations at Rs. 175.19 crore, up 2.48% QoQ from Rs. 170.95 crore in Q3 FY26 and up 53.39% YoY from Rs. 114.21 crore in Q4 FY25. Total income for Q4 FY26 is stated at Rs. 182.86 crore, up 2.53% QoQ from Rs. 178.34 crore, and up 45.15% YoY from Rs. 125.98 crore. The same release notes that total income is highlighted at Rs. 190 crore when other operating income is included. EBITDA for Q4 FY26 is stated at Rs. 62 crore, jumping 219% YoY. Profit before tax (PBT) for Q4 FY26 is stated at Rs. 47.40 crore, up 6.28% QoQ from Rs. 44.60 crore and up 129.21% YoY from Rs. 20.68 crore.

FY26 and FY25: annual scale and growth markers

For FY26, revenue from operations is stated at Rs. 632.63 crore, showing 59.65% YoY growth versus Rs. 396.25 crore in FY25. Total income for FY26 is stated at Rs. 679.69 crore, up 62.79% YoY from Rs. 417.51 crore. The article text also mentions FY25 financial highlights including total income of Rs. 410 crore (vs Rs. 214 crore in FY24), EBITDA of Rs. 101.8 crore (vs Rs. 41.6 crore), and PBT of Rs. 70.6 crore (vs Rs. 24.9 crore). For Q4 FY25, total income of Rs. 120 crore is cited, along with EBITDA of Rs. 25.4 crore and PBT of Rs. 20.7 crore. These reported numbers help investors contextualise whether quarterly estimates for FY27 are consistent with the company’s recent growth trajectory. They also give a sense of how quickly the income statement has expanded over FY24 to FY26.

Key quarterly checkpoints from FY26 disclosed results

The text includes multiple quarterly disclosures for FY26 that investors often use as checkpoints. For Q1 FY26, total income is stated at Rs. 138 crore, EBITDA at Rs. 34 crore (60% YoY change), and PAT at Rs. 21 crore (95% YoY change). The same Q1 FY26 disclosure mentions positive operating cash flow of Rs. 11 crore. For Q2 FY26, revenue is stated at Rs. 162 crore with EBITDA at Rs. 50 crore and PAT at Rs. 30 crore, with year-on-year change percentages also provided. For Q3 FY26, income is stated at Rs. 175 crore with EBITDA at Rs. 54 crore and PAT at Rs. 34 crore. Together, these points show an earnings profile that the market may compare against Q1 FY27 expectations when the new quarter is reported.

Alternate quarterly table: net sales and profitability line items

A separate quarterly table (all figures in Rs. crore) lists net sales and expenditure line items for Mar 2025 through Mar 2026. In that table, net sales rise from Rs. 11.86 crore (Mar 2025) to Rs. 36.81 crore (Mar 2026), while profit after tax is shown at Rs. 2.02 crore (Mar 2025) and Rs. 8.48 crore (Mar 2026). Other income in the same table is notable at Rs. 22.19 crore in Mar 2026. The table also shows operating profit at negative Rs. 3.48 crore in Mar 2026, despite profit before tax of Rs. 12.69 crore and profit after tax of Rs. 8.48 crore, reflecting the impact of other income in that data set. Adjusted EPS in the table moves from Rs. 0.44 (Mar 2025) to Rs. 1.84 (Mar 2026). Because the article text provides multiple reporting formats and metrics, readers typically track which set the market is focusing on in a given preview.

Valuation markers, targets and what investors may watch

At around Rs. 1,382, the preview note highlights a market cap of Rs. 6,356 crore and a P/E multiple of 52.3. The same preview includes a 12-month target range of Rs. 1,658 to 1,838, which sits alongside the Q1 FY27 revenue and PAT ranges. Separately, another data excerpt states an average 12-month price target of Rs. 1,174.25, with a high estimate of Rs. 1,310 and a low estimate of Rs. 972, indicating that target views can vary materially by source and method. From an events perspective, the key near-term catalyst remains the company’s Q1 FY27 results in the July to August 2026 window. Investors will likely compare the reported revenue and PAT against the stated ranges and also look for continuity with the FY26 growth numbers cited. Any management commentary or exchange filings around operational execution can also influence how the market interprets the print.

Company profile and registered office details

Senores Pharmaceuticals is described as a global research-driven pharmaceutical company engaged in developing and manufacturing a wide range of generic pharmaceutical products in the B2B segment, predominantly for regulated markets across therapeutic areas and dosage forms. The registered office details provided list: 1101 to 1103, 11th floor, South Tower, ONE 42 opposite Jayantilal Park, Ambali Bopal Road, Ahmedabad, Gujarat, 380054. The contact telephone number is listed as 079-29999857 and the email as cs@senorespharma.com. The website is provided as https://senorespharma.com. The text also lists board and key personnel, including Chairman (Non-Executive) Sanjay Majmudar and Company Secretary and Compliance Officer Nidhi Dilipbhai Kapadia.

Conclusion

Senores Pharmaceuticals’ Q1 FY27 is in focus due to published estimate ranges of Rs. 197 to 227 crore revenue and Rs. 28 to 36 crore PAT, with results expected in the July to August 2026 window. Recent disclosures cited for Q4 FY26 and FY26 provide context on growth and profitability trends that the market will use to judge the upcoming print. The next clear milestone is the company’s Q1 FY27 results announcement within the indicated window, after which estimates, targets, and valuation metrics will be reassessed based on reported numbers.